Optimisation of folate-mediated liposomal encapsulated arsenic trioxide for treating HPV-positive cervical cancer cells in vitro by Akhtar, Anam et al.
Middlesex University Research Repository
An open access repository of
Middlesex University research
http://eprints.mdx.ac.uk
Akhtar, Anam, Ghali, Lucy, Wang, Scarlet, Bell, Celia M., Li, Dong and Wen, Xuesong (2019)
Optimisation of folate-mediated liposomal encapsulated arsenic trioxide for treating
HPV-positive cervical cancer cells in vitro. International Journal of Molecular Sciences, 20 (9).
ISSN 1422-0067
Published version (with publisher’s formatting)
This version is available at: http://eprints.mdx.ac.uk/26531/
Copyright:
Middlesex University Research Repository makes the University’s research available electronically.
Copyright and moral rights to this work are retained by the author and/or other copyright owners
unless otherwise stated. The work is supplied on the understanding that any use for commercial gain
is strictly forbidden. A copy may be downloaded for personal, non-commercial, research or study
without prior permission and without charge.
Works, including theses and research projects, may not be reproduced in any format or medium, or
extensive quotations taken from them, or their content changed in any way, without first obtaining
permission in writing from the copyright holder(s). They may not be sold or exploited commercially in
any format or medium without the prior written permission of the copyright holder(s).
Full bibliographic details must be given when referring to, or quoting from full items including the
author’s name, the title of the work, publication details where relevant (place, publisher, date), pag-
ination, and for theses or dissertations the awarding institution, the degree type awarded, and the
date of the award.
If you believe that any material held in the repository infringes copyright law, please contact the
Repository Team at Middlesex University via the following email address:
eprints@mdx.ac.uk
The item will be removed from the repository while any claim is being investigated.
See also repository copyright: re-use policy: http://eprints.mdx.ac.uk/policies.html#copy
  
Int. J. Mol. Sci. 2019, 20, 2156; doi:10.3390/ijms20092156 www.mdpi.com/journal/ijms 
Article 
Optimisation of Folate-Mediated Liposomal 
Encapsulated Arsenic Trioxide for Treating HPV-
Positive Cervical Cancer Cells In Vitro 
Anam Akhtar, Lucy Ghali, Scarlet Xiaoyan Wang, Celia Bell, Dong Li and Xuesong Wen * 
Department of Natural Sciences, Middlesex University, The Burroughs, Hendon, London NW4 4BT, UK; 
a.akhtar@mdx.ac.uk (A.A.); l.ghali@mdx.ac.uk (L.G.); scarlet.wang@kcl.ac.uk (S.W); c.bell@mdx.ac.uk (C.B.); 
d.li@mdx.ac.uk (D.L.) 
* Correspondence: x.wen@mdx.ac.uk; Tel.: +44-208-411-4931 
Received: 10 April 2019; Accepted: 29 April 2019; Published: 30 April 2019 
Abstract: High-risk human papilloma virus (HPV) infection is directly associated with cervical 
cancer development. Arsenic trioxide (ATO), despite inducing apoptosis in HPV-infected cervical 
cancer cells in vitro, has been compromised by toxicity and poor pharmacokinetics in clinical trials. 
Therefore, to improve ATO’s therapeutic profile for HPV-related cancers, this study aims to explore 
the effects of length of ligand spacers of folate-targeted liposomes on the efficiency of ATO delivery 
to HPV-infected cells. Fluorescent ATO encapsulated liposomes with folic acid (FA) conjugated to 
two different PEG lengths (2000 Da and 5000 Da) were synthesised, and their cellular uptake was 
examined for HPV-positive HeLa and KB and HPV-negative HT-3 cells using confocal microscopy, 
flow cytometry, and spectrophotometer readings. Cellular arsenic quantification and anti-tumour 
efficacy was evaluated through inductively coupled plasma-mass spectrometry (ICP-MS) and 
cytotoxicity studies, respectively. Results showed that liposomes with a longer folic acid-
polyethylene glycol (FA-PEG) spacer (5000 Da) displayed a higher efficiency in targeting folate 
receptor (FR) + HPV-infected cells without increasing any inherent cytotoxicity. Targeted 
liposomally delivered ATO also displayed superior selectivity and efficiency in inducing higher cell 
apoptosis in HPV-positive cells per unit of arsenic taken up than free ATO, in contrast to HT-3. 
These findings may hold promise in improving the management of HPV-associated cancers. 
Keywords: arsenic trioxide (ATO); liposome; targeted drug delivery; cervical cancer; human 
papilloma virus (HPV); folate conjugation 
 
1. Introduction 
Cervical cancer is the second most common cancer in women worldwide and imposes a 
disproportionately high burden (>80%) on the developing world [1,2]. Since the 1990s, HPV infection 
has been established as the causal agent of cervical cancer with undisputed epidemiological studies, 
augmented by molecular technology [3,4]. Further studies have indicated that HPV infection might 
also be responsible for a subset of anal, vulvar, vaginal, penile, upper respiratory-digestive tract, and 
head and neck cancers [5–8]. Therefore, targeting HPV infection has become a priority in managing 
HPV-associated cancers, and an anti-HPV agent that can specifically be taken up by HPV-infected 
cells is ideally required to enhance treatment and minimise off-target toxicity to surrounding non-
HPV-infected cells and tissues [9]. 
Our research team, along with others, have shown that ATO, as a therapeutic drug, 
downregulated HPV oncogene expression and had an inhibitory effect on HPV-infected HeLa cells 
[10,11]. ATO is a potent clinical agent for the treatment of acute promyelocytic leukaemia and has 
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demonstrated significant clinical success for other haematological malignancies [12,13]. The 
mechanisms of ATO’s anti-cancer activity has been studied extensively, and various modes of action 
have been proposed, including the induction of apoptosis [14], mitochondrial toxicity [15,16], and the 
generation and accumulation of ROS [14,17]. In addition, ATO has been reported to interfere in other 
cellular events, for instance tubulin polymerisation, DNA repair, and cell cycle progression [16].  
Clinical response of solid tumours following ATO treatment, however, has been compromised 
by its severe side effects due to a requirement of much higher dosages for the treatment [18,19]. In 
vitro studies on HPV-associated cervical cancers have also clearly indicated that ATO is selective in 
its action only at low concentrations (~2 μM). When the dose was increased to 5 μM, most of the cells 
were killed from drug-induced toxicity, irrespective of HPV status [11].  
Therefore, an effective delivery system that can reduce ATO’s off-target toxicity and expand its 
clinical utility by increasing its accumulation at tumour sites, extending its circulation time in blood 
and increasing its specificity in targeting HPV-infected cancer cells, is needed. Encapsulating ATO in 
liposomes is one such strategy that has the potential to improve the drug’s therapeutic index by 
reducing its side effects and increasing drug concentration in tumours through an enhanced 
permeability and retention (EPR) effect [20]. In addition, if active targeting strategies are employed, 
the encapsulated drug can be directed to the target sites with minimal disturbance to the surrounding 
cells and tissues [21]. 
Active targeting, also referred to as ligand-mediated targeting, employs the specific affinity of 
ligands on the surface of the nanoparticles towards specific receptors or surface molecules 
overexpressed in target cells, tissues, or organs [22–26]. Aided by the EPR effect, which allows the 
nanoparticle to carry the drug payload to remain in the vicinity of the target cells, active targeting 
facilitates its cellular internalisation via the specific ligand–receptor interaction [27]. As a result, this 
approach is increasingly being recognised as an effective strategy to enhance the therapeutic indices 
of anti-cancer drugs. From our previous findings, FA was selected as the targeting ligand of choice 
for our target cells, as its corresponding FR was highly expressed on HPV-positive cells while 
minimally expressed for HPV-negative cell lines. FA conjugation to ATO liposomes thus has the 
promise to offer the desired selectivity for targeting HPV-infected cells.  
When folate-targeting nanoparticles were evaluated in preclinical settings, they showed 
promising results as both therapeutic and diagnostic agents [28–33]. However, there are quite a few 
parameters that need careful consideration to design an effective targeting system. Among them, 
optimisation of ligand density and ligand-conjugating polyethylene glycol (PEG) spacer length is 
crucial to enhance the uptake and efficiency of a drug-carrying liposomal construct. While a higher 
ligand density might be desirable to increase the binding avidity between the liposomes and the 
target antigens, it might also give rise to potential immunogenic concerns, along with the uncertainty 
of the effect on liposomal stability resulting from a high ligand density [34,35].  
The importance of PEG spacer length in FR targeting was succinctly established by Lee and Low 
for KB cells using both targeted and non-targeted liposomes [36]. Liposomes with folate tethered to 
a long PEG spacer (250 Å) displayed a higher uptake than either non-targeted or targeted liposomes 
with short spacer length [36]. Additionally, in another study by Gabizon et al. (1999), placing the 
ligand on a longer PEG spacer length of 3350 Da, as opposed to a 2000 Da PEG layer used for steric 
stabilisation, increased the uptake of conjugated liposomes substantially [37]. However, it has also 
been speculated that, if the ligand is conjugated to a longer PEG spacer than the other PEG chains 
involved in the PEG brush, the extra length of the long spacer might undergo mushroom-like folding, 
leading to limited exposure of the ligand [35]. Therefore, it might be preferable to have the same 
length spacer as the surrounding PEG brush [35]. This ambiguity in the literature about the 
appropriate spacer PEG length requires a thorough investigation for folate conjugation in order to 
achieve an enhanced drug uptake in a tumour-specific manner. 
As a complimentary strategy to EPR, ligand-functionalised nanoparticles offer the potential to 
further augment the efficacy of nanotherapeutics in treating diseases. Although there have been 
multiple studies reporting the enhanced uptake by FR-positive cells following folate conjugation to 
liposomes carrying the therapeutic payload [33,38–40], research that focuses on determining the 
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optimal spacer length for FA conjugation on liposomal physicochemical characteristics, inhibitory 
potency, and in vitro performance on cervical cancer cells with differing HPV status cannot be found. 
The aim of this study was to assess the effect of ligand spacer length on cellular uptake and inhibitory 
potency against HPV-positive cervical cancer cells in vitro and to identify the most suitable liposomal 
formulation for delivering ATO to cervical cancer cells. The uptake and anti-tumour efficacy of the 
liposomal formulations were examined using two cervical cancer cell lines, HeLa (HPV-positive) and 
HT-3 (HPV-negative), along with two control cell lines, KB (FR-positive) and A549 (FR-negative). 
2. Results 
2.1. Liposome Preparation and Characterisation 
Three labelled unconjugated and conjugated liposomal formulations (L1, unconjugated ATO 
liposomes; L2, FA-ATO liposomes with 2000 Da PEG spacer; L3, FA-ATO liposomes with 5000 Da 
PEG spacer) were synthesised, and the concentration of phospholipids, encapsulated arsenic, and 
nickel were determined by ICP-OES. All of the formulations were found to be efficiently loaded with 
arsenic, which was co-encapsulated with the transition metal ion Ni; loading efficiency (As/P) is 
depicted in Figure 1 (a). The loading efficiency was similar for all the liposomes, irrespective of the 
presence or absence of FA conjugation. The stability of the liposome suspension was analysed by 
storing it at 4 °C for a period of 4 weeks and calculating its loading efficiency every week (Figure 1 
(b). Less than 5% arsenic leaked from the liposomes in this time period. All of the liposomal 
formulations displayed similar storage stability. The mean size of control liposomes was determined 
by dynamic light scattering on a Zetasizer-Nano ZS as represented in Figure 1 (c). The DLS size 
measurement of L1, L2, and L3 were 138.5 ± 1.2 nm, 134.4 ± 1.7 nm, and 142.6 ± 3.1 nm respectively. 
The polydispersity index for the investigated vesicles ranged from 0.1 to 0.15, indicating a 
homogeneous population. 
(a) Loading efficiency (b) Stability study (c) Size measurement 
 
Figure 1. Characterisation of synthesised liposomes: (a) loading efficiency (%As/P), (b) ATO 
encapsulated in liposomes over four weeks of storage at 4 °C, and (c) diameter of liposomes as 
measured from Zetasizer with a polydispersity index of around 0.1. Conjugation or length of 
conjugating PEG spacer does not have any considerable effect on loading efficiency, stability over 
time in storage, or size of the liposomes. Data are means ± standard deviations of three replicate 
measurements of at least three independent experiments. 
2.2. Analysing Cellular Uptake by Differing Ligand–PEG Spacer Lengths in ATO Liposomes 
It has previously been reported in the literature that spacer length of the conjugated ligand 
impacts the efficacy of the cellular uptake of the nano-vehicle [41]. To assess this aspect, liposomes 
were conjugated with FA using a PEG spacer with the same length as the surrounding PEG brush 
(2000 Da) and a different formulation where FA was conjugated to a PEG spacer with a longer length 
(5000 Da) than the surrounding PEG brush (2000 Da). Previous studies of folate surface receptor 
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expression on the two cervical cancer cell lines investigated found that HeLa (HPV+) cells positively 
expressed FRs while HT-3 (HPV-) cells only minimally expressed the receptor. A positive control and 
a negative control cell line for FR expression, KB and A549, respectively, were also included to 
validate the robustness of the experiments, with their receptor expression reported in the order of KB 
> HeLa > HT-3 > A549 cells. Subsequently, the cellular uptake of the conjugated and unconjugated 
liposomes was investigated with techniques including confocal microscopy, flow cytometry, plate 
reader analysis, and ICP-MS arsenic quantification. 
Confocal laser scanning microscopy (CLSM) allowed for an evaluation of the intracellular fate 
of liposomes as a function of time for various cell lines. A confocal microscopic visualisation of the 
cellular association of DiI (1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine-5,5’-disulfonic 
acid)-labelled liposomes is depicted in Figure 2. The cells were treated for 2, 6, and 24 h, fixed in 4% 
paraformaldehyde and stained with DAPI (4′,6-diamidino-2-phenylindole) for nuclear imaging. By 
keeping all the parameters for confocal microscopic visualisation the same (PMT and % laser), it was 
possible to draw a comparative study of the cellular uptake of liposomes, with or without ligand 
conjugation. 
 KB HeLa HT-3 A549 
(a)     
L1 
    
L2 
    
L3 
    
(b)     
L1 
    
L2 
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L3 
    
(c)     
L1 
    
L2 
    
L3 
    
Figure 2. Confocal micrographs showing cellular uptake of DiI-labelled L1, L2, and L3 after treatment 
of (a) 2, (b) 6, and (c) 24 h. Cells were counterstained with DAPI to reveal the nuclear/DNA location. 
Among targeted liposomes, L3 were more efficient than L2 in being taken up by cells according to 
their FR expression, so the uptake in KB was highest followed by HeLa. HT-3 also took up more L3 
than L2, while A549 cells had no effect on their uptake from liposomal conjugation. Scale bar: 50 μm. 
Liposomes without surface functionalisation showed neither membrane accumulation nor 
cellular internalisation in any of the cell lines up to 24 h, as evidenced by the lack of liposomal 
fluorescence (Figure 2). In contrast, ligand conjugation, specifically with a 5000 Da PEG spacer length, 
mediated an efficient fluorescence uptake in FR-positive cell lines. After 2 h incubation, L3 was found 
to exhibit high cellular binding, for around 90% of KB cells, 25% of HeLa, and 5% of HT-3, as shown 
by the red fluorescence around the cell surface. L2 liposomes exhibited minor cellular uptake in KB 
cells. A549 had no effect of ligand conjugation on its liposomal uptake. 
KB cells demonstrated cellular internalisation and accumulation of L3 in their cytosol at a 
relatively large scale from the time course study, which was shown from the red fluorescence 
surrounding the DAPI-stained nuclei. L2 was also seen to enter most of the KB cells at 24 h treatment, 
but to a much lesser extent than L3, which displayed a higher efficiency of L3 for being taken up by 
the FR-positive cells. A similar trend was repeated for HeLa and HT-3 cells: L3 was more efficient in 
being taken up by the cells than L2, with L3 entering almost all the HeLa cells by the end of 24 h. The 
cellular uptake of conjugated liposomes (L2 or L3) in HeLa was always higher than HT-3. 
The results obtained from confocal microscopy analysis were further validated by flow 
cytometry (Figure 3). The cells from the four cell lines were exposed to fluorescently labelled 
liposomes for a period of 2, 6, and 24 h. A ratio of cells staining positive for conjugated liposomal (L2 
or L3) uptake to non-conjugated (L1) liposomal uptake was calculated for each cell line to determine 
the efficacy of FA conjugation in enhancing the liposomal cellular internalisation. The results 
indicated that cellular uptake in FR+ cells increased, even with simple folate conjugation (to a PEG 
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spacer with a length similar to that of the PEG brush)—by about 50 times for unconjugated liposomes 
in KB cells and to a much lesser extent in HeLa (2.1 times) and HT-3 (1.6 times) cells. When the PEG 
spacer length was taken into consideration and increased, i.e., from 2000 kD to 5000 kD, this further 
enhanced the uptake. After 24 h, L3, compared to L2, was taken up 1.2 times more in KB, twice as 
much in HeLa, and 1.3 times more in HT-3. A549, on the other hand, displayed a similar cellular 
uptake of liposomes, regardless of ligand conjugation. 
(a) (b) (c) 
   
Figure 3. Comparison of the cellular uptake of non-targeted (L1) and targeted liposomes (L2 and L3) 
by flow cytometry after (a) 2, (b) 6, and (c) 24 h treatment. An unpaired t-test was used to assess any 
significant difference in the uptakes between the conjugated liposomes, L2 and L3. L3 uptake was 
significantly higher in both KB and HeLa cells. Data are means ± standard deviations of three replicate 
measurements of at least three independent experiments. * p ≤ 0.05, ** p ≤ 0.01, and *** p ≤ 0.001. 
An additional uptake assay was performed in 96 well plates by reading the fluorescence of cells 
incubated with fluorescent targeted and non-targeted liposomes via a microplate reader. A 
comparison was drawn of the differential cellular uptake by analysing the ratio of fluorescence of 
cells incubated with targeted liposomes to non-targeted liposomes followed by blank correction. 
Results corroborated the findings from confocal and flow cytometry studies as depicted in Figure 4. 
Conjugated liposomes (both L2 and L3) were taken up in much higher proportions than non-
conjugated L1 in KB and HeLa cells, whereas A549 displayed no difference in uptake from ligand 
conjugation. HT-3 displayed some increase in uptake in the first six hours with L3 treatment after 
which the difference with L1 tapered off. 
(a) (b) (c) 
   
Figure 4. Comparison of cellular uptake of the three liposomal formulations L1, L2, and L3 by the 
four cell lines with plate reader analysis after (a) 2, (b) 6, and (c) 24 h treatment. L3 uptake was 
significantly higher than L2 in KB and HeLa. HT-3 cells also displayed a small but significantly 
enhanced uptake of L3 compared to L2. The difference between targeted and non-targeted liposomes 
decreased with time. Data are means ± standard deviations of three replicate measurements of at least 
three independent experiments. * p ≤ 0.05, ** p ≤ 0.01, and *** p ≤ 0.001. 
L3 liposomal formulation had a significantly higher uptake than L2 for FR-positive cells. They 
were taken up around 6.7 times more in KB cells and 4 times more in HeLa cells after 24 h. HT-3 also 
witnessed a 1.5 times higher uptake from L3 than L2, whereas A549 cells remained unaffected in their 
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liposomal uptake from ligand conjugation. In fact, conjugated liposomes were taken up slightly less 
than the non-conjugated liposomes by a factor of 0.9 in A549 cells. Similar to the flow cytometry 
results, the difference between the liposomal uptakes with ligand conjugation was reduced when the 
treatment time was increased to 24 h. This reduction, while being true for all the cell lines 
investigated, is more evident from 6 to 24 h than from 2 to 6 h. It is also more obvious for KB cells 
than HeLa cells. 
Cellular liposomal arsenic was quantified with ICP-MS after performing calibrations using 
arsenic ionic standards and Ga ion as an internal standard. For every experiment performed, we 
obtained a linear correlation for arsenic with squared correlation coefficients R2 >0.997. With this 
calibration, cellular arsenic was quantified by measuring the total amount of arsenic following 
digestion of the cells from the four cell lines treated with media only, ATO encapsulating conjugated 
and unconjugated liposomes for 6, 24, and 48 h. A comparative study of the liposomal treatment was 
then drawn for cellular arsenic, as depicted in Figure 5. 
(a) (b) (c) 
   
Figure 5. Arsenic concentration per cell as determined by ICP-MS in the four cell lines after (a) 6, (b) 
24, and (c) 48 h treatment with the unconjugated (L1) and conjugated (L2 and L3) liposomes. L3 was 
taken up more than L2 in FR-positive KB and HeLa cells. HT-3 had a higher uptake of liposomes in 
general, regardless of ligand conjugation. The arsenic concentration increased with time for all cell 
lines. Data shown is the mean ± SD of three independent experiments. * p ≤ 0.05, ** p ≤ 0.01, and *** p 
≤ 0.001. 
The results showed that, as the time of incubation increased, the cellular arsenic increased from 
all treatments for all four cell lines investigated. Quantifying arsenic clearly shows that increasing the 
ligand–PEG spacer length increases the liposomal uptake by FR-positive cells (Figure 5). After 6 h, 
L3 liposomes were taken up 2.1, 2.5, 1.3, and 0.8 times more in KB, HeLa, HT-3, and A549, 
respectively. It was obvious that A549 cells were not affected in their liposomal uptake by an increase 
in ligand-conjugating spacer length. The same trend was also observed with 24 and 48 h treatment. 
HT-3, despite showing a slight increase in L3 uptake compared to L2 uptake during the first six hours, 
reached a similar level with further prolonged treatments. 
Corroborating the previous findings, the cellular uptake studies by ICP-MS are consistent with 
the flow cytometry studies and plate reader analysis in that the difference between the uptakes of 
targeted and non-targeted liposomes decreases with time in FR+ cells. As KB cells had the highest 
folate expression on their cell surface, this decline was more pronounced than it was in HeLa cells. 
On the other hand, HT-3, with minimal expression of cell surface FRs, displayed a slight difference 
in the first few hours; however, with an increase in time, this difference was nullified, and targeted 
and non-targeted liposomes were taken up by the cells equally. As for A549 cells, being FR-negative, 
displayed no difference in the cellular uptakes from ligand conjugation as expected. Regarding the 
total arsenic content in the cells from the treatment, ICP-MS studies showed that the HT-3 cell line 
took up more liposomal arsenic in general than all four cell lines regardless of the ligand conjugation, 
while A549 took up the least. 
2.3. Analysing Cytotoxicity of Control Empty Liposomes with Differing Spacer Lengths of Conjugated 
Ligand 
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The results above clearly indicated the advantages of using a long PEG spacer to tether FA to 
the liposomes for enhancing their uptake in FR-positive cells. However, in order to employ them 
successfully as arsenic nanocarriers to manage cervical cancer, it becomes imperative to investigate 
any inherent cytotoxicity that they might possess due to the presence of longer PEG spacers. Since 
our focus is on cervical cancers and the presence or absence of HPV gene sequences, further 
experiments were carried out on HeLa, HT-3, and KB cells only. The KB cell line was included, since, 
despite being derived from epidermal mouth carcinoma, it had been contaminated with HeLa cells 
at some point. Therefore, it was positive for HPV-18 DNA sequences. Empty, unloaded liposomes of 
various formulations were synthesised and their cytotoxicity analysed on these cell lines via MTT 
assay at 48 h, as depicted in Figure 6. The dilutions employed for the empty liposomal treatment had 
their phospholipid concentrations corresponding to ATO liposomes with 5 μM encapsulated ATO 
concentration. At the dilutions used for treatment and the time period involved, none of the 
liposomes were toxic for any tested cell lines. With these results in consideration, L3 liposomes, out 
of the three, prove to be the best liposomal formulation to achieve targeting in FR-positive cell lines. 
KB HeLa HT-3 
   
Figure 6. Toxicity studies by MTT assay of the control empty liposomes (L1, L2, and L3) on KB, HeLa, 
and HT-3 cell lines after 48 h treatment. Increasing the spacer length for ligand conjugation did not 
result in increased cytotoxicity at the phospholipid concentrations at dilutions used for the treatment. 
L3 liposomes were non-toxic to all cell lines tested at 48 h, similar to L1 and L2, demonstrating the 
suitability of L3 as a drug carrier. Points refer to the means, and bars refer to ±SD, where n = 3.          
represents the concentrations of phospholipid at dilutions used for treatment of liposomal ATO. 
2.4. Quantitative Analysis of Cellular Uptake of Arsenic with Free and Liposomal Arsenic 
After establishing the superiority of L3 liposomes in the cellular uptake by FR+ cells, they were 
further investigated in terms of how they compared with ATO when delivered in free form. The cells 
were treated with L3, L1, free ATO, and media only as control for 6, 24, and 48 h, and their arsenic 
intake was quantified by ICP-MS (Figure 7). 
(a) (b) (c) 
   
Figure 7. Arsenic concentrations per cell in KB, HeLa, and HT-3 as determined by ICP-MS after (a) 6, 
(b) 24, and (c) 48 h treatment with only media, unconjugated ATO liposomes L1, FA-conjugated ATO 
liposomes L3, and free ATO with a 5 μM concentration. Data displayed are mean ± SD from five 
independent experiments. An unpaired t-test was used to calculate any significant difference in the 
arsenic intake from L3 and ATO treatments; ** p ≤ 0.01. L3 was taken up more than free ATO in KB at 
6 h, after which their uptakes reached a similar level when the time of treatment was increased to 24 
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and 48 h. The cellular arsenic intake from free ATO was higher than L3 in HeLa at 48 h, whereas for 
HT-3 it became significantly higher after 24 h. 
Results showed that after 6 h of treatment, targeted liposomes L3 were taken up more than free 
ATO in both KB and HeLa, with cellular arsenic concentration in the order of con < L1 < ATO < L3. 
Arsenic concentration due to L3 uptake was 2.1 and 1.3 times higher than that from ATO in KB and 
HeLa cells, respectively. Prolonging the incubation period to 24 h and further to 48 h resulted in 
reaching a similar level of cellular arsenic concentration from both the L3 and ATO treatments in KB 
cells. In contrast, with the prolonged incubation time, free ATO was taken up more than L3 in HeLa 
cells, 1.3 and 2.8 times more at 24 h and 48 h, respectively. In HT-3 cells, free ATO was always taken 
up more than the liposomal counterparts, both conjugated and non-conjugated, in the time periods 
tested. The results showed a consistent increase in the cellular arsenic concentration as the incubation 
time period increased for all the cell lines and the treatments, except the control non-treated sample. 
However, an unexpected observation was observed with the HT-3 cellular arsenic concentration 
following free ATO treatment, where instead of increasing from 24 to 48 h, it decreased from 207.4 fg 
to 150.8 fg per cell. 
2.5. Selectivity of Targeted Liposomal ATO in Killing HPV-Infected Cervical Cancer Cells 
With differing cellular uptakes of liposomal and free ATO, we further evaluated the cytotoxic 
response of cervical cancer cell lines of differing HPV statuses (HPV+ HeLa and HPV− HT-3) along 
with KB (HPV+) to the treatment of ATO delivered either in the free form or encapsulated within the 
chosen targeted liposomes with 48 h treatment (Figure 8a). The dose–response curve obtained from 
the MTT assay for the free drug and the liposomal drug revealed that liposomal encapsulation 
mitigated toxicity, except in the case of KB, where the targeted liposomes L3 induced more cell death 
than free ATO. At the dilutions used for treatment, i.e., at a 5 μM ATO concentration, the free drug 
caused more toxicity than L3 in HT-3 and HeLa cells. Cell death–uptake ratios for KB, HeLa, and HT-
3 cells (Figure 8b) indicated the level of cell death induced in the cell lines per unit of arsenic taken 
up by the cells. Targeted liposomal ATO was more effective than the free drug in inducing cell death 
per unit of arsenic uptake in both folate receptor positive KB and HeLa cell lines, whereas free ATO 
was more effective in inducing cell death in HT-3 cells. Additionally, between KB and HeLa cells, the 
liposomal ATO treatment was more effective for HeLa cells than KB cells per unit arsenic. 
(
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Figure 8. (a) MTT test analysis to compare cellular toxicity of targeted liposomal ATO with the free 
drug on HeLa, KB, and HT-3 cells at 48 h. Points refer to the means and bars refer to ±SD, where n = 
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3. Liposomal encapsulation attenuated drug toxicity to the cells in vitro, except for the KB cell line 
where L3 liposomes were more toxic than free ATO. (b) Ratios of cell death vs. uptake of targeted 
liposomal and free ATO for KB, HeLa, and HT-3 cells after 48 h treatment. Targeted liposomes 
induced highest toxicity per unit arsenic uptake in HeLa cells. Targeted liposomes were more effective 
in inducing cell death when they were corrected for intracellular ATO uptake than free ATO for both 
FR+ KB and HeLa cells. * p ≤ 0.05 and *** p ≤ 0.001.   points to 5 μM ATO concentrations that were 
typically used for treatment. 
3. Discussion 
The efficiency of any actively targeting system is assessed by two important parameters: 
delivering capacity and targeting specificity of the drug delivery vehicle [20]. The delivering capacity 
depends on the structure and composition of the nanoparticles [42,43]. In order to optimize an ATO 
drug nanocarrier for targeting HPV-infected cervical cells, we firstly optimised ATO encapsulating 
liposomes, with respect to size and charge, for use as delivery vehicles for our target cells [9]. The 
second parameter, targeting specificity, is mainly determined from the choice of the ligand and how 
it interacts with the off-target molecules and cells [20]. FA was selected as the targeting agent for 
folate receptors, which are overexpressed on the surface of targeted HPV cervical cells and minimally 
expressed on non-HPV cells. In addition, FA has other advantages as an ideal targeting agent, such 
as being inexpensive and stable with a low molecular weight as well as having simple conjugation 
chemistry and relative low immunogenicity [27,44,45]. FA has a very high affinity for the FR 
presented on tumour’s cell surface and is rapidly endocytosed [44]. Since FA is a vitamin required by 
the eukaryotic cells for the biosynthesis of nucleotide bases, any cargo attached to it remains within 
endosomes and is then released into cytoplasm rather than shuttled to the lysosome for destruction 
[27,44]. The folate-targeting of liposomal drug carriers has been reported to increase the therapeutic 
efficacy in a number of cases, but it requires careful optimisation for effective therapeutic applications 
for selected tumours [46,47]. 
The foremost necessity of synthesising an actively targeted nanoparticle is to extend its 
circulation times, as an increased nanoparticles’ affinity for the target antigens could not compensate 
for the natural clearance processes in most circumstances [20]. Actively targeted nanoparticles 
without sufficient steric stabilisation from a PEG layer tend to lose their receptor-binding ability due 
to non-specific interactions with colloidal proteins [48]. Additionally, since the physical stability of 
the targeted liposomes without the PEG layer was also not very well explored, in the initial 
experiments, only the ligand-conjugating PEG spacer was included in the liposomal mix to prepare 
a targeted ATO delivery system, without the addition of the brush-forming PEG layer. However, this 
resulted in unstable liposomal formulations, which caused aggregation during the drug loading 
itself, regardless of the length of the ligand PEG spacer. Adding mPEG2000-DSPE to the liposome mix 
stabilised the targeted formulations and prevented them from aggregating. This might be because 
surface-grafted PEG chains, even at low concentrations, could provide a sufficient steric barrier to 
prevent the fusion of liposomal membranes [49]. 
There was another parameter that required careful optimisation: the ligand density on the 
surface of the nanoparticle. Thermodynamically, the binding of a ligand to a receptor facilitates the 
binding of its neighbouring ligands; these multiple interactions lead to a clustering of the receptors, 
a wrapping of the membrane, and the eventual internalisation of the bound nanoparticle [50]. These 
multivalent interactions lead to an enhanced avidity of the nanoparticle towards the target cell and 
prevents its detachment from the cell surface. However, in vitro, a higher ligand density does not 
necessarily translate to an enhanced cellular uptake [51]. In some cases, it was shown that increasing 
the ligand density above a certain threshold resulted in saturation of the cooperative effects of the 
ligands, leading to unfavourable effects on cellular binding [52]. Moreover, the presence of a dense 
ligand covering on the nanoparticles was also known to make them more prone to being recognised 
by the cells of a mononuclear phagocytic system (MPS), which consequently led to a loss of their 
“stealth” surface characteristics [23]. Hence, in order to bypass any such negative effects and to ensure 
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high nanoparticle avidity to the surface receptors, it is necessary to optimise ligand density in the 
nanoparticles for every particular cancer type. 
Since this was an in vitro study, our investigation was primarily focused on the physico-chemical 
effects of ligand density on liposomal stability and subsequent cellular uptake. There have been 
reports of ligand molar ratio to range from 0.03 to 0.5% in the literature for folate-targeting liposomes 
[30,37,53–55]. In our experiments, it was observed that using 0.3 mol % DSPE-PEG2000-FA and 1.7 mol 
% mPEG2000-DSPE in the liposomal mixture formed stable L2 liposomes. However, the same (0.3 mol 
%) or higher amount of DSPE-PEG5000-FA could not be used to prepare stable L3 liposomes, and this 
invariably led to the aggregation of liposomes as soon as they were synthesised, despite the presence 
of a stabilising PEG2000 brush layer. After adjusting molar ratios of components, employing 0.1 mol % 
DSPE-PEG5000-FA and 1.9 mol % mPEG2000-DSPE yielded stable L3 liposomal formulations. In 
addition, preliminary confocal uptake studies of L2 liposomes, synthesised with 0.3 mol % or 0.1 mol 
% DSPE-PEG2000-FA, did not show any significant difference between cellular uptakes in HeLa cells. 
Henceforth, the same ratio (0.1 mol %) was used to prepare both L2 and L3 liposomes for comparison 
purposes. The instability of L3 liposomes with higher ligand density might be explained by studies 
where high folate density on the surface of nanoparticles were known to produce dimers, trimers, 
and quartet self-assembled folate structures, causing an aggregation of nanoparticles, with a longer 
ligand-conjugating PEG spacer expediting the process [56]. 
At a molar ratio employed for synthesising targeted liposomes, ligand conjugation had no effect 
on either the size of the nanoparticles, nor the arsenic loading efficiency and stability (Figure 1). All 
formulations (L1, L2, and L3) had similar sizes, i.e. around 140 nm, and achieved a high loading 
efficiency, with an arsenic-to-phospholipid molar ratio of 0.25. Our stability tests showed that all the 
liposomes, irrespective of ligand conjugation, were homogeneous and stable with a loss of less than 
10% arsenic over four weeks of storage at 4 °C (see Figure 1). 
Owing to a possibility that PEG brush might mask the targeting abilities of the ligand if it is 
conjugated to a PEG spacer of equal length, we synthesised L2 liposomes with an FA-PEG spacer of 
2000 Da and L3 liposomes with a longer PEG-FA of 5000 Da in length with a surrounding 2000 Da 
PEG brush. As the previous studies employed FA-PEG3350 [57], we chose to use a longer PEG spacer 
length of 5000 Da for making targeted liposomes and thus to investigate any increase in cellular 
uptake along with any inherent toxicity that might arise from employing longer PEG spacers for 
ligand conjugation. We evaluated the differences in cellular uptake for the liposomal formulations 
using four different techniques: confocal microscopy, flow cytometry, fluorescence reading via a 
plate reader, and cellular arsenic quantification via ICP-MS. 
Keeping all settings and parameters the same for comparative analysis, confocal microscopic 
images showed the superiority of using a longer PEG spacer for ligand conjugation (Figure 2). After 
the initial 2 h incubation, L3 liposomes clearly displayed a superior cell surface attachment in around 
80% of FR+ KB cells, in contrast to 10% of KB cells with L2 liposomes. Additionally, around 20% of 
the HeLa cells showed membrane attachment with L3, but none was observed with either L2 or L1. 
Some attachment (around 5%) was also seen with L3 in HT-3 cells. A549 (an HPV-negative cell line) 
showed no cellular association with L3, which demonstrates the superiority of the conjugated ligand 
to specifically target HPV-positive cells. These results are in accordance with the hypothesis that 
folate-targeted arsenic loaded liposomes would be efficiently and selectively taken up by FR-positive 
cells and that, since FR expression in cell lines is in the order of KB > HeLa >> HT-3 > A549, the cellular 
uptake of targeted liposomes would also follow the same pattern. As the incubation period was 
increased to 4, 6, and eventually 24 h, KB cells saw a widespread internalisation and accumulation of 
L3 in their cytosol. L3 was also taken up in almost all of the HeLa cells and around 20% of the HT-3 
cells. In contrast, L2, albeit more effective than L1, was visibly less effective than L3 in being taken 
up by FR+ cells. Based on the confocal images of KB and HeLa cells in particular, the cell surface 
association of targeted liposomes at 2 h and then the subsequent internalisation and accumulation 
within the cytoplasm at 24 h was significant, indicating endocytosis. 
These results are consistent with results from both the flow cytometric analysis of cellular uptake 
of fluorescent liposomes and the fluorescence reading from the plate reader, which confirmed the 
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superior and selective uptake of L3 liposomes by FR+ cells (Figures 3 and 4). ICP-MS studies further 
validated the findings and the results showed that the cellular arsenic content from L3 uptake was 
almost three times as much as the L2 uptake in KB cells and twice that of HeLa cells after 24 h (Figure 
5). This enhanced uptake was, however, not significant in the case of HT-3 cells, owing to the weak 
FR expression by these cells. FR-negative A549 cells displayed a similar uptake for all the liposomes, 
irrespective of conjugation or non-conjugation. 
This enhanced ATO cellular uptake from L3 liposomes could be explained by folate-receptor-
mediated endocytosis. In order to confirm this, future work will be carried out to evaluate drug 
cellular uptake by blocking FRs with free folates prior to FR-Lip-ATO exposure to the cells. [36]. This 
would provide useful information for us to understand the uptake mechanism of folate-conjugated 
liposomes by the target cells. Drugs carried by delivery vehicles could be internalised in the cells via 
different endocytic pathways, which might prevent the drug from reaching the desired targeted 
cellular organelle and therefore affecting or even diminishing the therapeutic effect [58]. Of the 
different pathways proposed for nanomedicinal uptake, clathrin-mediated endocytosis via specific 
receptor–ligand interaction is the best characterised and has been reported to be the preferred 
pathway for particles up to 200 nm in size [59]. However, recent studies have suggested that folate-
conjugated nanoparticles utilise both clathrin- and caveolae-receptor-mediated endocytosis 
pathways [60], with the preferred route possibly being dependent on the size of the drug carrier [58]. 
In one study, it was reported that the uptake of 50 nm nanoparticles followed the clathrin-mediated 
endocytic pathway, whilst the uptake of 250 nm particles was dominated by caveolae-mediated 
endocytosis [58]. Since the size of our targeted liposomes was around 140 nm in diameter, they might 
be predominantly employing the clathrin-mediated endocytic pathway. However, further 
investigations are needed to confirm this hypothesis. 
It was evident from the flow cytometric and plate reader analysis that the difference between 
the cellular uptake of conjugated and non-conjugated liposomes decreased with prolonging the 
exposure time (Figures 3 and 4), which might be due to two contributing factors: an increase in non-
specific uptake of unconjugated liposomes and a subsequent decrease in the uptake of conjugated 
liposomes due to a possible saturation of the targeted receptors on the cell surface. This effect was 
most pronounced for KB cells followed by HeLa. This hypothesis was corroborated after quantifying 
cellular arsenic via ICP-MS. Results showed that after an initial high surge of targeted liposomal 
arsenic uptake by FR+ cells, the rate at which they were taken up almost invariably slowed down in 
comparison with non-targeted liposomes. This led to a bridging of the gap between their uptakes in 
cells. 
Results clearly demonstrated that FA conjugation to liposomes, even to a PEG spacer of similar 
length as the surrounding PEG brush, was able to selectively target FR-positive cells. However, their 
targeting efficiency increased considerably when FA was conjugated to a longer PEG spacer, making 
L3 the logical choice as a delivery vehicle for arsenic to FR rich HeLa and KB cells with HPV infection. 
However, for it to function as a successful delivery vehicle, any cytotoxicity generated needs to be 
evaluated. Since we intended to build on our work investigating the therapeutic potential of arsenic 
against HPV-infected cervical cancers and the time period chosen for our previous studies had been 
48 h, all the liposomal formulations were tested for any intrinsic cytotoxicity by incubating empty 
liposomes for 48 h with HeLa, HT-3, and KB cells (all positive for HPV infection). The dilutions of 
liposomes tested for toxicity included ones that corresponded with the liposomal concentration with 
encapsulated 5 μM ATO and that were used for treatment. All the liposomes, including L3, were 
found to be non-toxic at the dilutions to be used for treatment (Figure 6). This finding was in 
agreement with the study by Peng et al. (2013), who observed that the conjugated docetaxel delivery 
systems targeting prostrate specific membrane antigen with a longer spacer length had no significant 
toxicity in vitro or in vivo in major organs of treated mice bearing a C4-2 tumour xenograft [41]. 
Kawano and Maitani [61] also reported a higher cellular association of liposomal doxorubicin with a 
longer ligand–PEG spacer without a significant increase in cytotoxicity. 
Consequently, the inherent non-cytotoxicity of L3 liposomes along with their superior targeting 
abilities led us to select them as an optimised design for a targeted ATO nano-carrier. Further in vitro 
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analysis was also carried out with L3 as the conjugated liposomes, L1 as their unconjugated 
counterparts, and free ATO on HPV-positive KB and HeLa cells and HPV-negative HT-3 cells. 
Cellular uptake studies showed that, usually, arsenic was transported more readily within the 
cells when the free form was applied (Figure 7). However, owing to the very high FR expression of 
KB cells, these cells were shown to be most amenable towards folate targeting and consequent 
liposomal uptake, with L3 liposomes transporting twice as much arsenic in the first six hours of 
treatment. This trend was also seen with HeLa cells, albeit to a lesser extent. As treatment time 
increased, however, we reported an equalising of the cellular arsenic concentration between L3- and 
free-ATO-treated KB cells, whilst an increasing arsenic concentration with free ATO treatment in 
HeLa cells was surprisingly observed. In HT-3 cells, however, the free form of the drug was always 
taken up more so than the liposomally delivered forms, with little difference between L1 and L3 
uptake. 
The cells were further incubated with free and targeted liposomal ATO with a 5 μM 
concentration for a period of 48 h, and their cytotoxicity was assessed via MTT assay (Figure 8a). As 
expected, KB cells displayed maximum vulnerability towards L3 treatment, where L3 liposomes 
induced more cell death than the free drug. In contrast, free ATO generated a higher toxicity than the 
liposomal formulation for both HeLa and HT-3 cells. The cell death–uptake ratio indicates the cell 
death induced per unit of arsenic uptake and is an effective means of comparing the efficacy of a 
treatment on different cell populations. Our results indicated that, for targeted liposomal treatment, 
this ratio was higher for HPV-positive HeLa and KB cells than it was for HPV-negative HT-3 cells 
(Figure 8b). Moreover, targeted liposomes were more efficient in inducing cell death than free ATO 
in FR-positive cells per unit of arsenic taken up, in contrast to HT-3 cells. Interestingly, targeted 
liposomal ATO was found to be most effective in inducing its response towards HeLa cells, which 
indicates a certain susceptibility of the cell line towards liposomal treatment, an aspect that warrants 
further research. 
4. Materials and Methods 
4.1. Materials 
Folate free RPMI-1640 media, Gibco McCoy’s 5A (modified) medium, foetal bovine serum (FBS), 
penicillin–streptomycin (5000U/mL), 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine-5,5’-
disulfonic Acid (DiI), nitric acid, Trypan Blue, isopropanol, NaH2PO4 (sodium dihydrogen 
phosphate), Na2HPO4 (disodium hydrogen phosphate), and Trypsin-EDTA were purchased from 
Fisher Scientific (Loughborough, UK). Soy phosphatidylcholine (PC), cholesterol (Chol), 
methoxy(polyethyleneglycol)-2000-distearoyl-phosphatidylethanolamine (mPEG-DSPE), 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-folate(polyethylene glycol)-2000 (DSPE-PEG2000-
FA), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-folate (polyethylene glycol)-5000 
(DSPE-PEG5000-FA) were purchased from Avanti Polar Lipids (Alabaster, AL, USA). VECTASHIELD 
Hard Set Mounting Media with DAPI were obtained from Vector Labs (Peterborough, UK). 
Phosphate-buffered saline (PBS), ATO, nickel acetate, dimethyl sulfoxide (DMSO), thiazolyl blue 
tetrazolium bromide powder (MTT), Whatman Anotop 0.1 μm syringe filters, and dialysis tubing 
were purchased from Sigma (Welwyn Garden City, UK). Ham’s F-10 Nutrient Mix, methanol, and 
dichloromethane were obtained from Thermofisher (Paisley, UK). 
4.2. Liposome Preparation and Characterisation 
Liposomes prepared for this study were labelled with DiI and had compositions as follows: (a) 
untargeted liposomes (L1), PC/Chol/mPEG-DSPE/DiI = 52.5/45/2/0.5 mol %; (b) folate-targeted 
liposome with a 2000 MW PEG-FA spacer (L2), PC/Chol/mPEG-DSPE/DSPE-PEG2000-FA/DiI = 
52.5/45/1.9/0.1/0.5 mol %; folate-targeted liposomes with a 5000 MW PG-FA spacer (L3), 
PC/Chol/mPEG-DSPE/DSPE-PEG5000-FA/DiI = 52.5/45/1.9/0.1/0.5 mol %. Liposomes were prepared as 
described elsewhere with slight modifications [62]. Briefly, the lipids were dissolved in 1:2 (v/v) 
methanol/dichloromethane at room temperature. The lipid mixtures were deposited on the side wall 
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of a rotary glass vial by removing the solvent with nitrogen. The dried lipid films were hydrated in 
730 mM nickel acetate (Ni(OAc)2) aqueous solutions for 1 h with gentle rotation. This process led to 
the spontaneous formation of multilamellar PEGylated liposomes. The liposome suspension was 
subsequently subjected to 10 freeze–thaw cycles (freezing in liquid nitrogen for 3 min and thawing 
in a 37 °C water bath for 3 min and downsized via 0.1 μm Anotop filters. Extruded liposomes were 
dialysed overnight against 10 mM sodium phosphate buffer at pH 7 to remove unencapsulated 
Ni(OAc)2. The nickel acetate-encapsulated liposomes were then incubated with a 20 mM ATO 
solution at room temperature with gentle rolling for 5 h. The unencapsulated ATO was further 
removed by dialysis overnight. The concentrations of phospholipids (P), encapsulated arsenic (As), 
and nickel (Ni) within the liposomes were determined by an inductively coupled plasma optical 
emission spectrometer (ICP-OES; Thermo-Scientific iCap 6500 ICP, Stafford, UK), and loading 
efficiency (As/P ratio) was calculated. Their mean liposomal size was calculated via dynamic light 
scattering on a Zetasizer-Nano ZS (Malvern Instruments, Malvern, UK). Liposomal stability over a 
period of a month was assessed by analysing their loading efficiency every week, while liposomes 
were stored at 4 °C in buffers of pH 7.4. 
4.3. Cell Culture 
HPV-positive and -negative cervical cancer cell lines, HeLa, and HT-3, along with FR-positive 
and -negative control cell lines, human nasopharyngeal epidermal carcinoma KB, and lung 
carcinoma A549 cells, respectively (ATCC, Middlesex, UK), were employed in this study. HeLa and 
KB cells were grown in folate-free RPMI-1640 media, HT-3 cells in McCoy’s 5A (Modified) media, 
and A549 cells in Ham’s F-10 nutrient mix, supplemented with 10% FBS and 1% penicillin–
streptomycin for a minimum of 2 months before each experiment in 75 cm2 flasks. The cells were 
grown in a humidified incubator containing 5% CO2 and 95% air at 37 °C until they reached 90% 
confluence. The following experiments were set up to investigate cellular uptake following liposomal 
ATO exposure for different time intervals: confocal microscopic visualisation, flow cytometry, 
spectrophotometer analysis, and quantification of cellular arsenic uptake by ICP-MS studies. Cellular 
toxicity was investigated via MTT assay. 
4.4. Qualitative Cellular Uptake Analysis by Confocal Microscopic Visualisation of Liposomal Arsenic 
Cells were plated 24–48 h before each experiment, on sterile 22 mm coverslips inside 6-well 
plates at a density of 5 ×  10  /mL. Following attachment, the cells were exposed to DiI-labelled 
liposomes (L1, L2, and L3) for various time intervals at 37 °C in the incubator. The employed 
liposomal dilution had an arsenic concentration of 18 μmol/L. After the intended time period, the 
spent media were removed, and cells were washed three times with PBS and fixed with PBS-buffered 
4% paraformaldehyde at 25 °C for 8 min. The coverslips were again washed with PBS and mounted 
on a slide using DAPI containing anti-fade ProLong Gold reagent. The fluorescence emitted from 
each slide was observed via a fluorescent confocal microscope at 570 nm and 460 nm for DiI and 
DAPI, respectively (Leica Microsystems, Wetzlar, Germany). 
4.5. Flow Cytometric Analysis of Liposomal Arsenic Uptake 
Cells were seeded at 5 × 105/mL in six-well culture plates and grown overnight before they were 
exposed to the DiI-labelled liposomal formulations with an arsenic concentration of 18 μmol/L for 
various time intervals at 37 °C. After the intended time interval, the cells were washed thrice with 
PBS, trypsinized, washed twice by PBS, and then collected into FACS tubes with 500 μL of PBS. All 
samples were analysed using FACSCalibur (BD, Oxford, UK). For DiI, the maximum excitation was 
obtained with an He–Ne laser at 555 nm, and fluorescence emission intensities were observed at 570 
nm using an FL-2 filter. For each sample, a minimum of 10,000 cells were collected. Data were 
analysed using CellQuest Pro software from BD Biosciences. The ratio of cells staining positive with 
labelled FA-conjugated liposomes (L2 and L3) to cells staining positive for labelled unconjugated 
liposomes (L1) was calculated to yield an estimate of the differences in the uptake of liposomes of 
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different formulations. All measurements were performed in duplicates from at least three different 
experiments. 
4.6. Plate Reader Analysis of Liposomal Uptake by Cells 
Cells were seeded at 1 × 105/mL in 96-well plates and allowed to attach overnight. Cells were 
further exposed to labelled liposomes at arsenic concentration of 18 μmol/L for 2, 6, and 24 h at 37 °C. 
Following treatment, the cells were washed twice with PBS and the fluorescence measured via BMG 
LabTech FLUOstar Omega Plate Reader (Bucks, UK). As with flow cytometric analysis, the ratio of 
cells staining positive with FA-labelled conjugated liposomes (L2 and L3) to cells staining positive 
for labelled unconjugated liposomes (L1) was calculated and analysed. 
4.7. Quantitative Analysis of Liposomal Drug Uptake via ICP-MS 
Cellular uptake was analysed for different treatments for 6, 24, and 48 h by ICP-MS. Cells from 
the four different cell lines were first seeded at a density of 1 × 106 cells/flask into sixteen 75 cm2 flasks. 
After a 24 h cell attachment, they were treated with liposomal formulations as mentioned above and 
a free drug with an arsenic concentration of 10 μmol/L. Following the incubation interval, the cells 
were washed with PBS, trypsinised, and counted prior to collection in Falcon tubes for further 
analysis. The cells were lysed by adding 2 mL of nitric acid while vortexing and heating at a 
temperature of 60 °C for 5 min and were topped up with 8 mL of deionised water. Arsenic 
concentration was analysed using ICP-MS (Thermo Fisher XSeries2, Paisley, UK) and corrected to the 
cell number and total volume accordingly. 
4.8. In Vitro Cellular Cytotoxicity Assay 
Cytotoxicity of various liposomal formulations of ATO was determined by the MTT assay as 
described previously [28]. Briefly, the experiment was set up in a 96-well plate, where the toxicity of 
control empty liposomes was investigated by taking an initial starting amount containing 0.5 mM of 
phospholipid concentration and diluting it in 1:10 ratio to another 6 wells. Simultaneously, the 
toxicity of ATO encapsulating liposomes was calculated by taking the starting amount of 30 μM of 
ATO concentration, diluting to a 1:6 ratio at a final working arsenic concentration of 5 μM for treating 
the cells. The wells were seeded with HeLa, HT-3, KB, and A549 at a density of 0.6 million cells per 
mL and incubated at 37 °C in the humidified incubator for 48 h. After the intended incubation, the 
spent media was carefully removed and 50 μL of MTT solution was added to each well. Cells were 
further incubated for 30 min at 37 °C. The MTT solution was then removed and 100 μL of propanol 
was added per well for at least 30 min incubation at 37 °C to dissolve crystals. The absorbance of this 
coloured solution was quantified by measuring at a wavelength of 570 nm from BMG LabTech 
FLUOstar Omega Plate Reader (Bucks, UK). 
4.9. Statistical Analysis 
Statistical analysis described in experimental sections was done using Minitab17. Statistical 
significance was determined by a two-sample t-test. p < 0.05 was considered significant. For flow 
cytometry, statistical analysis was carried out automatically though BD Calibur software provided. 
For confocal microscopy results, the average number of positively stained cells in a total of six fields 
for each sample was calculated, and average percentages were recorded. 
5. Conclusions 
The success of a targeted drug delivery system, tailored to the specific cancer under 
investigation, depends on the thorough optimisation of the nano-carrier’s various parameters. In this 
study, we synthesised folate-targeted, ATO-encapsulated liposomes and examined the effect of 
increasing the ligand spacer length on cellular uptake and inhibitory potency against FR-positive 
cancer cells in vitro, with particular emphasis on HPV-infected FR-positive cervical cancer cells. 
Folate targeting, particularly when the ligand was attached to a longer PEG spacer, led to an 
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appreciable enhancement in cellular uptake by FR-positive cancer cells. This formulation, along with 
being efficient and highly specific, had no inherent toxicity of its own at the dilutions used for the 
treatment, making it suitable to be used as the delivery vehicle of ATO to HPV-positive cervical 
cancer cells. Future preclinical studies are warranted to elucidate the role of EPR-mediated passive 
targeting and folate-active targeting in vivo and to investigate nanoparticle clearance/potential 
toxicity utilising tumour-bearing mice. Our results suggest that further investigation of the molecular 
mechanisms behind the ATO action delivered via liposomes for targeted liposomal ATO cancer 
treatment is warranted. 
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Abbreviations 
% percentage 
μg microgram 
μl microliter 
μM micromolar 
A549 human lung epithelial cancer cell line 
As arsenic 
ATO arsenic trioxide 
C centigrade 
Chol cholesterol 
CLSM confocal laser scanning microscopy 
Da dalton 
DAPI 4′,6-diamidino-2-phenylindole 
DiI 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine-5,5’-disulfonic acid 
DLS dynamic light scattering 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DSPE-PEG2000 methoxypolyethyleneglycol-distearoyl-phosphatidylethanolamine with mPEG MW 
2000 Da 
DSPE-PEG2000-
Folate 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-folate(polyethylene glycol)-
2000 with mPEG MW2000 Da 
DSPE-PEG5000-
Folate 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-folate(polyethylene glycol)-
5000 with mPEG MW5000 Da 
EPR enhanced permeability and retention effect 
FA folic acid 
FACS fluorescence activated cell sorting 
FBS fetal bovine serum 
FITC fluorescein isothiocyanate  
fg femtogram 
FR folate receptor 
Ga gallium 
h hour(s) 
HeLa human cervical epithelial cells of adenocarcinoma 
HPV human papilloma virus 
HT-3  human cervical cancer cell line (HPV-negative) 
ICP-MS inductively coupled plasma-mass spectrometer 
ICP-OES inductively coupled plasma-optical emission spectrometer 
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KB human nasopharyngeal cell line contaminated with HeLa cells 
kDa kilodalton 
Lipo liposome 
mAb monoclonal antibody 
min minute(s) 
mM  millimolar 
mol molarity 
MPS mononuclear phagocytic system 
MTT 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide 
NaH2PO4 sodium dihydrogen phosphate 
Na2HPO4 disodium hydrogen phosphate 
Ni nickle 
Ni(OAc)2 nickle acetate 
nm nanometre 
P phospholipids 
PBS phosphate buffered saline 
PC phosphatidyl choline 
PEG polyethylene glycol 
PMT photomultiplier tube 
SD standard deviation 
UK United Kingdom 
USA United States of America 
v/v volume by volume 
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